Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cellectar Biosciences

0.3851
+0.00802.12%
Volume:1.41M
Turnover:544.39K
Market Cap:17.75M
PE:-0.28
High:0.3950
Open:0.3900
Low:0.3744
Close:0.3771
Loading ...

Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025

GlobeNewswire
·
05 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
03 Mar

BRIEF-Cellectar Biosciences Inc - Receives Nasdaq Notice On Minimum Bid Price Requirement

Reuters
·
01 Feb

BRIEF-Cellectar Biosciences Inc Files For Offering Of Up To 19.2 Million Shares By The Selling Stockholders - SEC Filing

Reuters
·
30 Jan

Cellectar Biosciences Inc Files for Offering of up to 19.2 Mln Shares by the Selling Stockholders - SEC Filing

THOMSON REUTERS
·
30 Jan

Cellectar Biosciences files to sell 19.22M shares of common stock for holders

TIPRANKS
·
30 Jan

Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase During the JP Morgan Healthcare Conference

THOMSON REUTERS
·
13 Jan

Cellectar Biosciences price target lowered to $1 from $7 at Maxim

TIPRANKS
·
20 Dec 2024

Cellectar Biosciences Plunges on Pursuit of Strategic Options for Cancer Drug Candidate, 60% Workforce Cut

Dow Jones
·
12 Dec 2024

Cellectar Biosciences Strategic Shift and Workforce Reduction

TIPRANKS
·
12 Dec 2024

Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options

Benzinga
·
12 Dec 2024

Nasdaq Surges Over 1%; US Inflation Rises In-Line With Expectations

Benzinga
·
11 Dec 2024

BRIEF-Cellectar Biosciences Says Workforce Reduction Expected To Decrease Annual Operating Costs

Reuters
·
11 Dec 2024

Cellectar Biosciences Inc - Estimates to Incur Severance Costs of Approximately $1.7 Million

THOMSON REUTERS
·
11 Dec 2024

BUZZ-Cellectar Biosciences plunges on potential cancer drug sale

Reuters
·
11 Dec 2024

Cellectar Biosciences trading resumes

TIPRANKS
·
11 Dec 2024